Search research articles
Contact Us
Filters
Showing results (141-150 of 257) with videos related to
Page
of 26
Sort By:
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Trials
|
August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
Victoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Dermatology and Therapy
|
August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
The Journal of Investigative Dermatology
|
October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
American Journal of Clinical Dermatology
|
October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Dermatology and Therapy
|
February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Clinical and Experimental Dermatology
|
May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort
Oras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
Drug Safety
|
June 11, 2016
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Megan E B Clowse, Steven R Feldman, John D Isaacs, et al.
The British Journal of Dermatology
|
November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control study
Kayleigh J Mason, Oras A Alabas, Nick Dand, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 257) with videos related to
Sort By:
Page
of 26
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Trials
|
August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
Victoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Dermatology and Therapy
|
August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
The Journal of Investigative Dermatology
|
October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
American Journal of Clinical Dermatology
|
October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Dermatology and Therapy
|
February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Clinical and Experimental Dermatology
|
May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort
Oras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
Drug Safety
|
June 11, 2016
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Megan E B Clowse, Steven R Feldman, John D Isaacs, et al.
The British Journal of Dermatology
|
November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control study
Kayleigh J Mason, Oras A Alabas, Nick Dand, et al.
Page
of 26